{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T14:57:17Z","timestamp":1763564237044,"version":"3.37.3"},"reference-count":33,"publisher":"American Association of Psychiatric Pharmacists (AAPP)","issue":"4","license":[{"start":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T00:00:00Z","timestamp":1661212800000},"content-version":"vor","delay-in-days":22,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Olanzapine (OLZ) is a second generation antipsychotic that is approved for the treatment of schizophrenia, bipolar disorder type 1 as monotherapy (acute manic or mixed episodes, maintenance), or as an add-on to lithium or valproate (manic or mixed episodes). It is one of the most effective antipsychotics for the treatment of schizophrenia, but concerns remain due to its significant metabolic adverse effects. Notably, OLZ has one of the highest rates of weight gain among all antipsychotic drugs. Previous studies report on potential mitigation of weight gain with opioid antagonists. A systematic review was conducted to summarize the impact of these agents on weight and BMI when used as adjuncts to OLZ.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A systematic review of randomized controlled trials was conducted with 3 searches between March 2, 2021 and March 27, 2022.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Six studies met inclusion criteria, 5 of which assessed OLZ and samidorphan (SAM) and 1 of which assessed OLZ and naltrexone compared with OLZ monotherapy. A total of 1752 patients were included with 952 receiving SAM and 14 receiving naltrexone as an adjunct to OLZ. SAM was shown to mitigate OLZ-induced weight gain by 1.0 kg. Only 1 study assessed naltrexone with no statistically significant results for weight gain.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Discussion<\/jats:title>\n                  <jats:p>SAM is effective at reducing OLZ-induced weight gain. Naltrexone did not reduce OLZ-induced increases in weight or BMI. However, there is a paucity of data on other opioid antagonists as adjuncts to OLZ treatment to prevent increases in weight or BMI.<\/jats:p>\n               <\/jats:sec>","DOI":"10.9740\/mhc.2022.08.254","type":"journal-article","created":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T17:09:41Z","timestamp":1661274581000},"page":"254-262","source":"Crossref","is-referenced-by-count":8,"title":["Opioid antagonists to prevent olanzapine-induced weight gain: A systematic review"],"prefix":"10.9740","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0811-6628","authenticated-orcid":true,"given":"S. Andrea","family":"Laguado","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6181-138X","authenticated-orcid":true,"given":"Stephen R.","family":"Saklad","sequence":"additional","affiliation":[{"name":"2 Director of Psychiatric Pharmacy Program and Clinical Professor, The University of Texas at Austin College of Pharmacy, Austin, Texas; Director of Psychiatric Pharmacy Program and Clinical Professor, University of Texas Health San Antonio, Pharmacotherapy and Research Center, San Antonio, Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4719","published-online":{"date-parts":[[2022,8,23]]},"reference":[{"key":"2022082317084923800_i2168-9709-12-4-254-b01","unstructured":"Lilly\n              Eli\n             and\n\t\t\t\t\t\tCompanyLLC. ZYPREXA\n          (olanzapine); 1997\n          [cited\n          2021\n          Aug 11]. Available from: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=d5051fbc-846b-4946-82df-341fb1216341"},{"key":"2022082317084923800_i2168-9709-12-4-254-b02","doi-asserted-by":"crossref","unstructured":"Lieberman\n              JA,\n            \n            \n              Stroup\n              TS,\n            \n            \n              McEvoy\n              JP,\n            \n            \n              Swartz\n              MS,\n            \n            \n              Rosenheck\n              RA,\n            \n            \n              Perkins\n              DO,\n            \n            et al.\n          \n          Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.\n\t\t\t\t\tN Engl J Med.\n\t\t\t\t\t2005;353(12):1209-23.\n\t\t\t\t\tDOI: 10.1056\/NEJMoa051688. PubMed PMID: 16172203.","DOI":"10.1056\/NEJMoa051688"},{"key":"2022082317084923800_i2168-9709-12-4-254-b03","doi-asserted-by":"crossref","unstructured":"Leucht\n              S,\n            \n            \n              Cipriani\n              A,\n            \n            \n              Spineli\n              L,\n            \n            \n              Mavridis\n              D,\n            \n            \n              Orey\n              D,\n            \n            \n              Richter\n              F,\n            \n            et al.\n          \n          Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis.\n\t\t\t\t\tLancet.\n\t\t\t\t\t2013;382(9896):951-62.\n\t\t\t\t\tDOI: 10.1016\/S0140-6736(13)60733-3. PubMed PMID: 23810019.","DOI":"10.1016\/S0140-6736(13)60733-3"},{"key":"2022082317084923800_i2168-9709-12-4-254-b04","doi-asserted-by":"crossref","unstructured":"Bushe\n              CJ,\n            \n            \n              Slooff\n              CJ,\n            \n            \n              Haddad\n              PM,\n            \n            \n              Karagianis\n              JL.\n            \n          \n          Weight change by baseline BMI from three-year observational data: findings from the Worldwide Schizophrenia Outpatient Health Outcomes Database.\n\t\t\t\t\tJ Psychopharmacol.\n\t\t\t\t\t2013;27(4):358-65.\n\t\t\t\t\tDOI: 10.1177\/0269881112473789. PubMed PMID: 23343595.","DOI":"10.1177\/0269881112473789"},{"key":"2022082317084923800_i2168-9709-12-4-254-b05","doi-asserted-by":"crossref","unstructured":"Huhn\n              M,\n            \n            \n              Nikolakopoulou\n              A,\n            \n            \n              Schneider-Thoma\n              J,\n            \n            \n              Krause\n              M,\n            \n            \n              Samara\n              M,\n            \n            \n              Peter\n              N,\n            \n            et al.\n          \n          Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis.\n\t\t\t\t\tLancet.\n\t\t\t\t\t2019;394(10202):939-51.\n\t\t\t\t\tDOI: 10.1016\/S0140-6736(19)31135-3.","DOI":"10.1016\/S0140-6736(19)31135-3"},{"key":"2022082317084923800_i2168-9709-12-4-254-b06","doi-asserted-by":"crossref","unstructured":"Cooper\n              SJ,\n            \n            \n              Reynolds\n              GP,\n            \n            \n              Barnes\n              TRE,\n            \n            \n              England\n              E,\n            \n            \n              Haddad\n              PM,\n            \n            \n              Heald\n              A,\n            \n            et al.\n          \n          BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment.\n\t\t\t\t\tJ Psychopharmacol.\n\t\t\t\t\t2016;30(8):717-48.\n\t\t\t\t\tDOI: 10.1177\/0269881116645254. PubMed PMID: 27147592.","DOI":"10.1177\/0269881116645254"},{"key":"2022082317084923800_i2168-9709-12-4-254-b07","doi-asserted-by":"crossref","unstructured":"Wang\n              Y,\n            \n            \n              Wang\n              D,\n            \n            \n              Cheng\n              J,\n            \n            \n              Fang\n              X,\n            \n            \n              Chen\n              Y,\n            \n            \n              Yu\n              L,\n            \n            et al.\n          \n          Efficacy and tolerability of pharmacological interventions on metabolic disturbance induced by atypical antipsychotics in adults: a systematic review and network meta-analysis.\n\t\t\t\t\tJ Psychopharmacol.\n\t\t\t\t\t2021;35(9):1111-9.\n\t\t\t\t\tDOI: 10.1177\/02698811211035391. PubMed PMID: 34311625.","DOI":"10.1177\/02698811211035391"},{"key":"2022082317084923800_i2168-9709-12-4-254-b08","doi-asserted-by":"crossref","unstructured":"Zhuo\n              C,\n            \n            \n              Xu\n              Y,\n            \n            \n              Liu\n              S,\n            \n            \n              Li\n              J,\n            \n            \n              Zheng\n              Q,\n            \n            \n              Gao\n              X,\n            \n            et al.\n          \n          Topiramate and metformin are effective add-on treatments in controlling antipsychotic-induced weight gain: a systematic review and network meta-analysis.\n\t\t\t\t\tFront Pharmacol.\n\t\t\t\t\t2018;9:\n\t\t\t\t\t1393.\n\t\t\t\t\tDOI: 10.3389\/fphar.2018.01393. PubMed PMID: 30546312; PubMed Central PMCID: PMC6280187.","DOI":"10.3389\/fphar.2018.01393"},{"key":"2022082317084923800_i2168-9709-12-4-254-b09","doi-asserted-by":"crossref","unstructured":"Bodnar\n              RJ.\n            \n          \n          Endogenous opioids and feeding behavior: a decade of further progress (2004\u20132014). A festschrift to Dr.\n\t\t\t\t\tAbba Kastin. Peptides.\n\t\t\t\t\t2015;72:\n\t\t\t\t\t20-33.\n\t\t\t\t\tDOI: 10.1016\/j.peptides.2015.03.019. PubMed PMID: 25843025.","DOI":"10.1016\/j.peptides.2015.03.019"},{"key":"2022082317084923800_i2168-9709-12-4-254-b10","doi-asserted-by":"crossref","unstructured":"Yeomans\n              MR,\n            \n            \n              Gray\n              RW.\n            \n          \n          Opioid peptides and the control of human ingestive behaviour.\n\t\t\t\t\tNeurosci Biobehav Rev.\n\t\t\t\t\t2002;26(6):713-28.\n\t\t\t\t\tDOI: 10.1016\/S0149-7634(02)00041-6. PubMed PMID: 12479844.","DOI":"10.1016\/S0149-7634(02)00041-6"},{"key":"2022082317084923800_i2168-9709-12-4-254-b11","doi-asserted-by":"crossref","unstructured":"Parker\n              KE,\n            \n            \n              Johns\n              HW,\n            \n            \n              Floros\n              TG,\n            \n            \n              Will\n              MJ.\n            \n          \n          Central amygdala opioid transmission is necessary for increased high-fat intake following 24-h food deprivation, but not following intra-accumbens opioid administration.\n\t\t\t\t\tBehav Brain Res.\n\t\t\t\t\t2014;260(2):131-8.\n\t\t\t\t\tDOI: 10.1016\/j.bbr.2013.11.014. PubMed PMID: 24257074; PubMed Central PMCID: PMC4451003.","DOI":"10.1016\/j.bbr.2013.11.014"},{"key":"2022082317084923800_i2168-9709-12-4-254-b12","doi-asserted-by":"crossref","unstructured":"Chaudhary\n              AMD,\n            \n            \n              Khan\n              MF,\n            \n            \n              Dhillon\n              SS,\n            \n            \n              Naveed\n              S.\n            \n          \n          A review of samidorphan: a novel opioid antagonist.\n\t\t\t\t\tCureus.\n\t\t\t\t\t2019;11(7):e5139.\n\t\t\t\t\tDOI: 10.7759\/cureus.5139. PubMed PMID: 31523568; PubMed Central PMCID: PMC6741386.","DOI":"10.7759\/cureus.5139"},{"key":"2022082317084923800_i2168-9709-12-4-254-b13","doi-asserted-by":"crossref","unstructured":"Todtenkopf\n              M,\n            \n            \n              Dean\n              R,\n            \n            \n              Brunner\n              M,\n            \n            \n              Knopp\n              M,\n            \n            \n              Deaver\n              D.\n            \n          \n          The novel opioid receptor modulator RDC-0313 (ALKS 33) reduces olanzapine-induced weight gain and adipose accretion in a novel nonhuman primate model of antipsychotic-related weight changes. ACNP 2011 Hot Top Poster Present III-206.\n\t\t\t\t\tNeuropsychopharmacology.\n\t\t\t\t\t2011;36(Suppl 1):S324-449.\n\t\t\t\t\tDOI: 10.1038\/npp.2011.293. PubMed Central PMCID: PMC6863370.","DOI":"10.1038\/npp.2011.293"},{"key":"2022082317084923800_i2168-9709-12-4-254-b14","doi-asserted-by":"crossref","unstructured":"Cunningham\n              JI,\n            \n            \n              Eyerman\n              DJ,\n            \n            \n              Todtenkopf\n              MS,\n            \n            \n              Dean\n              RL,\n            \n            \n              Deaver\n              DR,\n            \n            \n              Sanchez\n              C,\n            \n            et al.\n          \n          Samidorphan mitigates olanzapine-induced weight gain and metabolic dysfunction in rats and non-human primates.\n\t\t\t\t\tJ Psychopharmacol.\n\t\t\t\t\t2019;33(10):1303-16.\n\t\t\t\t\tDOI: 10.1177\/0269881119856850. PubMed PMID: 31294646; PubMed Central PMCID: PMC6764014.","DOI":"10.1177\/0269881119856850"},{"key":"2022082317084923800_i2168-9709-12-4-254-b15","unstructured":"US FDA [Internet].\n          Drugs@FDA: FDA-approved drugs\n          [cited\n          2021\n          Nov 4]. Available from: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&varApplNo=213378"},{"key":"2022082317084923800_i2168-9709-12-4-254-b16","doi-asserted-by":"crossref","unstructured":"Martin\n              WF,\n            \n            \n              Correll\n              CU,\n            \n            \n              Weiden\n              PJ,\n            \n            \n              Jiang\n              Y,\n            \n            \n              Pathak\n              S,\n            \n            \n              DiPetrillo\n              L,\n            \n            et al.\n          \n          Mitigation of olanzapine-induced weight gain with samidorphan, an opioid antagonist: a randomized double-blind phase 2 study in patients with schizophrenia.\n\t\t\t\t\tAm J Psychiatry.\n\t\t\t\t\t2019;176(6):457-67.\n\t\t\t\t\tDOI: 10.1176\/appi.ajp.2018.18030280. PubMed PMID: 30845818.","DOI":"10.1176\/appi.ajp.2018.18030280"},{"key":"2022082317084923800_i2168-9709-12-4-254-b17","unstructured":"Page\n              MJ,\n            \n            \n              McKenzie\n              JE,\n            \n            \n              Bossuyt\n              PM,\n            \n            \n              Boutron\n              I,\n            \n            \n              Hoffmann\n              TC,\n            \n            \n              Mulrow\n              CD,\n            \n            et al.\n          \n          The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.\n\t\t\t\t\tPLoS Med.\n\t\t\t\t\t2021;18(3):e1003583.\n\t\t\t\t\tDOI: 10.1371\/journal.pmed.1003583. PubMed PMID: 33780438; PubMed Central PMCID: PMC8007028."},{"key":"2022082317084923800_i2168-9709-12-4-254-b18","doi-asserted-by":"crossref","unstructured":"Brunette\n              MF,\n            \n            \n              Correll\n              CU,\n            \n            \n              O'Malley\n              SS,\n            \n            \n              McDonnell\n              D,\n            \n            \n              DiPetrillo\n              L,\n            \n            \n              Jiang\n              Y,\n            \n            et al.\n          \n          Olanzapine plus samidorphan (ALKS 3831) in schizophrenia and comorbid alcohol use disorder. J Clin Psychiatry.\n          2020;\n\t\t\t\t\t81(2):19m12786.DOI: 10.4088\/JCP.19m12786. PubMed PMID: 32160422.","DOI":"10.4088\/JCP.19m12786"},{"key":"2022082317084923800_i2168-9709-12-4-254-b19","doi-asserted-by":"crossref","unstructured":"Correll\n              CU,\n            \n            \n              Newcomer\n              JW,\n            \n            \n              Silverman\n              B,\n            \n            \n              DiPetrillo\n              L,\n            \n            \n              Graham\n              C,\n            \n            \n              Jiang\n              Y,\n            \n            et al.\n          \n          Effects of olanzapine combined with samidorphan on weight gain in schizophrenia: a 24-week phase 3 study.\n\t\t\t\t\tAm J Psychiatry.\n\t\t\t\t\t2020;177(12):1168-78.\n\t\t\t\t\tDOI: 10.1176\/appi.ajp.2020.19121279. PubMed PMID: 32791894.","DOI":"10.1176\/appi.ajp.2020.19121279"},{"key":"2022082317084923800_i2168-9709-12-4-254-b20","doi-asserted-by":"crossref","unstructured":"Potkin\n              SG,\n            \n            \n              Kunovac\n              J,\n            \n            \n              Silverman\n              BL,\n            \n            \n              Simmons\n              A,\n            \n            \n              Jiang\n              Y,\n            \n            \n              DiPetrillo\n              L,\n            \n            et al.\n          \n          Efficacy and safety of a combination of olanzapine and samidorphan in adult patients with an acute exacerbation of schizophrenia. J Clin Psychiatry.\n          2020;\n\t\t\t\t\t81(2):19m12769.DOI: 10.4088\/JCP.19m12769. PubMed PMID: 32141723.","DOI":"10.4088\/JCP.19m12769"},{"key":"2022082317084923800_i2168-9709-12-4-254-b21","doi-asserted-by":"crossref","unstructured":"Silverman\n              BL,\n            \n            \n              Martin\n              W,\n            \n            \n              Memisoglu\n              A,\n            \n            \n              DiPetrillo\n              L,\n            \n            \n              Correll\n              CU,\n            \n            \n              Kane\n              JM.\n            \n          \n          A randomized, double-blind, placebo-controlled proof of concept study to evaluate samidorphan in the prevention of olanzapine-induced weight gain in healthy volunteers.\n\t\t\t\t\tSchizophr Res.\n\t\t\t\t\t2018;195(4):245-51.\n\t\t\t\t\tDOI: 10.1016\/j.schres.2017.10.014. PubMed PMID: 29158012.","DOI":"10.1016\/j.schres.2017.10.014"},{"key":"2022082317084923800_i2168-9709-12-4-254-b22","doi-asserted-by":"crossref","unstructured":"Taveira\n              TH,\n            \n            \n              Wu\n              W-C,\n            \n            \n              Tschibelu\n              E,\n            \n            \n              Borsook\n              D,\n            \n            \n              Simonson\n              DC,\n            \n            \n              Yamamoto\n              R,\n            \n            et al.\n          \n          The effect of naltrexone on body fat mass in olanzapine-treated schizophrenic or schizoaffective patients: a randomized double-blind placebo-controlled pilot study.\n\t\t\t\t\tJ Psychopharmacol.\n\t\t\t\t\t2014;28(4):395-400.\n\t\t\t\t\tDOI: 10.1177\/0269881113509904. PubMed PMID: 24218048.","DOI":"10.1177\/0269881113509904"},{"key":"#cr-split#-2022082317084923800_i2168-9709-12-4-254-b23.1","unstructured":"Alkermes, Inc.  A phase 2, randomized, multicenter, safety, tolerability, and dose-ranging study of samidorphan, a component of ALKS 3831, in adults with schizophrenia treated with olanzapine [published  2021  Sep  10"},{"key":"#cr-split#-2022082317084923800_i2168-9709-12-4-254-b23.2","unstructured":"cited 2022 May 19].Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT01903837"},{"key":"2022082317084923800_i2168-9709-12-4-254-b24","doi-asserted-by":"crossref","unstructured":"Duggan\n              L,\n            \n            \n              Fenton\n              M,\n            \n            \n              Rathbone\n              J,\n            \n            \n              Dardennes\n              R,\n            \n            \n              El-Dosoky\n              A,\n            \n            \n              Indran\n              S.\n            \n          \n          Olanzapine for schizophrenia. Cochrane Database Syst Rev.\n          2005;\n\t\t\t\t\t2:CD001359.DOI: 10.1002\/14651858.CD001359.pub2. PubMed PMID: 15846619.","DOI":"10.1002\/14651858.CD001359.pub2"},{"key":"2022082317084923800_i2168-9709-12-4-254-b25","doi-asserted-by":"crossref","unstructured":"Leucht\n              S,\n            \n            \n              Crippa\n              A,\n            \n            \n              Siafis\n              S,\n            \n            \n              Patel\n              MX,\n            \n            \n              Orsini\n              N,\n            \n            \n              Davis\n              JM.\n            \n          \n          Dose-response meta-analysis of antipsychotic drugs for acute schizophrenia.\n\t\t\t\t\tAm J Psychiatry.\n\t\t\t\t\t2020;177(4):342-53.\n\t\t\t\t\tDOI: 10.1176\/appi.ajp.2019.19010034. PubMed PMID: 31838873.","DOI":"10.1176\/appi.ajp.2019.19010034"},{"key":"2022082317084923800_i2168-9709-12-4-254-b26","doi-asserted-by":"crossref","unstructured":"American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care.\n          2004;27(2):596-601.\n\t\t\t\t\tDOI: 10.2337\/diacare.27.2.596. PubMed PMID: 14747245.","DOI":"10.2337\/diacare.27.2.596"},{"key":"2022082317084923800_i2168-9709-12-4-254-b27","doi-asserted-by":"crossref","unstructured":"Yagoda\n              S,\n            \n            \n              Graham\n              C,\n            \n            \n              Simmons\n              A,\n            \n            \n              Arevalo\n              C,\n            \n            \n              Jiang\n              Y,\n            \n            \n              McDonnell\n              D.\n            \n          \n          Long-term safety and durability of effect with a combination of olanzapine and samidorphan in patients with schizophrenia: results from a 1-year open-label extension study.\n\t\t\t\t\tCNS Spectr.\n\t\t\t\t\t2021;26(4):383-92.\n\t\t\t\t\tDOI: 10.1017\/S1092852920001376. PubMed PMID: 32393412.","DOI":"10.1017\/S1092852920001376"},{"key":"2022082317084923800_i2168-9709-12-4-254-b28","doi-asserted-by":"crossref","unstructured":"Kahn\n              RS,\n            \n            \n              Silverman\n              BL,\n            \n            \n              DiPetrillo\n              L,\n            \n            \n              Graham\n              C,\n            \n            \n              Jiang\n              Y,\n            \n            \n              Yin\n              J,\n            \n            et al.\n          \n          A phase 3, multicenter study to assess the 1-year safety and tolerability of a combination of olanzapine and samidorphan in patients with schizophrenia: results from the ENLIGHTEN-2 long-term extension.\n\t\t\t\t\tSchizophr Res.\n\t\t\t\t\t2021;232:\n\t\t\t\t\t45-53.\n\t\t\t\t\tDOI: 10.1016\/j.schres.2021.04.009. PubMed PMID: 34015555.","DOI":"10.1016\/j.schres.2021.04.009"},{"key":"2022082317084923800_i2168-9709-12-4-254-b29","doi-asserted-by":"crossref","unstructured":"Tek\n              C,\n            \n            \n              Ratliff\n              J,\n            \n            \n              Reutenauer\n              E,\n            \n            \n              Ganguli\n              R,\n            \n            \n              O'Malley\n              SS.\n            \n          \n          A randomized, double-blind, placebo-controlled pilot study of naltrexone to counteract antipsychotic-associated weight gain: proof of concept.\n\t\t\t\t\tJ Clin Psychopharmacol.\n\t\t\t\t\t2014;34(5):608-12.\n\t\t\t\t\tDOI: 10.1097\/JCP.0000000000000192. PubMed PMID: 25102328.","DOI":"10.1097\/JCP.0000000000000192"},{"key":"2022082317084923800_i2168-9709-12-4-254-b30","doi-asserted-by":"crossref","unstructured":"Hay\n              JW,\n            \n            \n              Smeeding\n              J,\n            \n            \n              Carroll\n              NV,\n            \n            \n              Drummond\n              M,\n            \n            \n              Garrison\n              LP,\n            \n            \n              Mansley\n              EC,\n            \n            et al.\n          \n          Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR drug cost task force report\u2014part I.\n\t\t\t\t\tValue Health.\n\t\t\t\t\t2010;13(1):3-7.\n\t\t\t\t\tDOI: 10.1111\/j.1524-4733.2009.00663.x.","DOI":"10.1111\/j.1524-4733.2009.00663.x"},{"key":"2022082317084923800_i2168-9709-12-4-254-b31","unstructured":"IBM Micromedex(R) [Internet].\n          Red Book, Micromedex(R)\n          [cited\n          2022\n          May 22]. Available from: https:\/\/www-micromedexsolutions-com.ezproxy.lib.utexas.edu\/micromedex2\/librarian\/CS\/A22466\/ND_PR\/evidencexpert\/ND_P\/PFActionId\/redbook.FindRedBook?"},{"key":"2022082317084923800_i2168-9709-12-4-254-b32","doi-asserted-by":"crossref","unstructured":"Manu\n              P,\n            \n            \n              Dima\n              L,\n            \n            \n              Shulman\n              M,\n            \n            \n              Vancampfort\n              D,\n            \n            \n              De Hert\n              M,\n            \n            \n              Correll\n              CU.\n            \n          \n          Weight gain and obesity in schizophrenia: epidemiology, pathobiology, and management.\n\t\t\t\t\tActa Psychiatr Scand.\n\t\t\t\t\t2015;132(2):97-108.\n\t\t\t\t\tDOI: 10.1111\/acps.12445. PubMed PMID: 26016380.","DOI":"10.1111\/acps.12445"}],"container-title":["Mental Health Clinician"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/meridian.allenpress.com\/mhc\/article-pdf\/12\/4\/254\/3106246\/i2168-9709-12-4-254.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/meridian.allenpress.com\/mhc\/article-pdf\/12\/4\/254\/3106246\/i2168-9709-12-4-254.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T16:23:31Z","timestamp":1731687811000},"score":1,"resource":{"primary":{"URL":"https:\/\/mhc.kglmeridian.com\/view\/journals\/mhcl\/12\/4\/article-p254.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,1]]},"references-count":33,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,8,23]]},"published-print":{"date-parts":[[2022,8,1]]}},"URL":"https:\/\/doi.org\/10.9740\/mhc.2022.08.254","relation":{},"ISSN":["2168-9709"],"issn-type":[{"type":"electronic","value":"2168-9709"}],"subject":[],"published":{"date-parts":[[2022,8,1]]}}}